Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms
Exscientia plc and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
“We are driven to develop the next generation of oncology treatments that can offer meaningful benefits and improve the lives of our patients”
The research collaboration will utilise Exscientia’s precision medicine platform to identify novel anti-cancer, cell-intrinsic small-molecule compounds based on jointly identified therapeutic targets. Promising candidates will advance for further development with the team at MD Anderson’s Therapeutics Discovery division. The collaborators anticipate that successful target discovery programs may be advanced into proof-of-concept clinical trials at MD Anderson.
Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1
“We are driven to develop the next generation of oncology treatments that can offer meaningful benefits and improve the lives of our patients,” said Philip Jones, Ph.D., vice president of Therapeutics Discovery and head of the Institute for Applied Cancer Science (IACS) at MD Anderson. “This collaboration is built upon Exscientia’s AI-driven precision medicine platform, the strength of MD Anderson’s drug discovery and development engine, and the expertise of our clinical research teams. Our ultimate goal is to decrease the time we spend in drug development and accelerate novel targeted therapies into the clinic.”
Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics. IACS is a core component of MD Anderson’s Therapeutics Discovery division, an integrated team of researchers, physicians and drug development experts working to advance impactful new therapies.
“We are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments. Artificial intelligence has opened up new possibilities in cancer research, enabling us to use deep learning multi-omics within our precision medicine platform to test potential drug candidates in Exscientia’s patient tissue models,” said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. “Further, our platform holds the potential to stratify patients even in the early discovery stage, allowing us to efficiently design drug candidates that are most likely to be impactful for people with cancer.”
Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.